Kamada's Plans For Emphysema Drug Delayed By Years After MAA Withdrawal
Executive Summary
Kamada has withdrawn its European approval application for an inhaled version of its emphysema drug Glassia – a move that shocked investors because of the company's continued insistence data from a failed pivotal study would be enough to convince regulators.
You may also be interested in...
Kamada slumps on reticence to explain 'positive signal' in AAT trial
Kamada of Israel believes that despite missing the primary endpoint in a Phase II/III trial, positive secondary endpoint data and results from a recently initiated US Phase II trial will be enough to persuade regulators to approve its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD or inherited emphysema).
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.